ArticleBMJ open2025
Awareness and prevalence of the symptoms of testosterone deficiency: a cross-sectional survey of community-dwelling men in the UK.
Article in BMJ open, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- The effect of stress on testosterone and sexual function.International journal of impotence research · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
objectivesNon-specific symptoms of testosterone deficiency (TD) and lack of awareness impact diagnosis and appropriate treatment. This study aimed to characterise the awareness of key symptoms of TD in community-dwelling men and contextualise this against the reported prevalence of these symptoms.
designCross-sectional survey comprising 54 questions (including assessment of symptoms as per the qADAM questionnaire and where relevant, men's experiences while on TD treatment). The survey was distributed through online media channels, Prolific and academic networks.
settingCommunity-dwelling men in the UK. OUTCOME MEASURES: Associations between age, participant demographics and a 'positive' qADAM score were assessed using logistic regression. A positive qADAM score was defined as self-rated 'poor' or 'terrible' libido or erection strength or rating 3 of the other questionnaire domains as 'poor' or 'terrible'.
resultsOf 973 men, 49% indicated high likelihood of TD using qADAM scores-5% were formally diagnosed. Men over 50 years of age had 1.54-2.0 times higher odds of TD compared with men aged <40 (p<0.05). 31% reported low libido, 27% reported reduced erectile strength and 26% reported over three symptoms associated with TD. Despite this, 55% were unfamiliar with symptoms/signs associated with TD. Only 7% of individuals expressed satisfaction with their access to low testosterone resources in the UK. Key barriers to seeking medical advice or treatment included lack of awareness of symptoms (39%), financial costs (35%) and stigma surrounding hormonal health (29%).
conclusionsAlmost half of the responders exhibited a burden of TD-associated symptoms, but under 5% had a formal diagnosis. These findings suggest significant gaps between symptom awareness and access to treatment options.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.